Quanterix (QTRX) investor relations material

Executive summary

• Q2 2026 revenue was $32.9 million, up 34% year-over-year, driven by the Akoya acquisition, but below expectations due to market softness and execution challenges.

• Leadership changes and commercial reorganization included new executives in commercial, diagnostics, operations, and finance roles to improve execution.

• Strategic focus on Alzheimer's diagnostics, with FDA 510(k) submission for LucentAD Complete and expanded insurance coverage and CMS premium pricing.

• Completed Akoya integration, achieving $85 million in annualized cost synergies and ERP system integration.

• Net loss for Q2 2026 was $48.9 million, impacted by a $26.9 million goodwill impairment and $19.3 million IPR&D impairment.

Financial highlights

• Q2 2026 revenue: $32.9 million; cash and marketable securities at quarter-end: $96.9 million.

• Adjusted (non-GAAP) gross margin improved to 47.9% from 41.8% year-over-year; GAAP gross margin was 38.5%.

• Adjusted EBITDA loss for Q2 2026 was $10.0 million, improved from $13.7 million year-over-year.

• Operating expenses for Q2 2026: $62.1 million (GAAP), including $26.9 million goodwill impairment; non-GAAP operating expenses: $31.8 million.

• Net loss per share for Q2 2026 was $1.04, compared to $0.77 in Q2 2025.

Outlook and guidance

• 2026 revenue guidance lowered to $142–$148 million (previously $169–$174 million); non-GAAP gross margin expected at 48–50%.

• Cash flow breakeven now targeted for 2027 (previously year-end 2026); year-end 2026 cash expected at ~$80 million, with no debt.

• Q3 revenue expected to be flat or slightly above Q2; commercial actions anticipated to drive more material growth in 2027.